TSVT News and Press, 2seventy bio Inc. From 03/01/24

2seventy bio, Inc . (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferenc...

2024-02-26 19:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-16 12:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-05 07:28:26 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: All Focus On Execution Bristol-Myers Squibb: Massive Discount Spells Opportunity Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation Bristol-Myers Squibb beats i...

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Oncologic Drugs Advisory Committee (ODAC) on March 15, 2024, to r...

2024-02-02 07:49:26 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: Don't Waver Over Undue Fears And Doubts Bristol Myers Squibb: Might Be Approaching A Bottom In 2024 Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal Bristol-Myers Squib...

2024-01-31 15:47:11 ET More on 2seventy bio 2seventy bio: An Overload Of Troubles At This Small Pharma 2seventy bio, Inc. (TSVT) Q3 2023 Earnings Call Transcript 2seventy stock rises as Regeneron acquires R&D assets Bristol-Myers Squibb wins EU nod for ex...

2024-01-30 09:31:39 ET A Massachusetts-based %Biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that the company has agreed to sell its pipeline of investigational cell therapies to Regeneron pharmaceuticals Inc. (Nasdaq: REGN) fo...

2024-01-30 07:24:33 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...

- Company to focus exclusively on commercialization and development of Abecma , in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Greg...